Therapeutic potential of the anti-diabetic agent metformin in targeting the skin cancer stem cell diaspora

Experimental Dermatology

Volumn 23, Issue 5, 2014, Pages 345-346

  Reddi, Anand ^a   Powers, Matthew A ^a,d   Dellavalle, Robert P ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Food Science and Human Nutrition   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Cancer diaspora; Cancer stem cell; Chemoprevention; Diabetes mellitus; Melanoma; Metastasis; Metformin; Skin cancer; Squamous cell carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; ANTIDIABETIC AGENT;

CANCER INHIBITION; CANCER PREVENTION; CANCER STEM CELL; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; HUMAN; INFLAMMATION; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY TUMOR; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MELANOMA; METASTASIS; SKIN NEOPLASMS;

CHEMOPREVENTION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MELANOMA; METFORMIN; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; SKIN NEOPLASMS;

EID: 84899496189     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12349     Document Type: Letter

References (34)

1. Sporn M B. Cancer Res 1976: 36(7 PT 2): 2699-2702.
2. Sporn M B, Dunlop N M, Newton D L et al. Fed Proc 1976: 35: 1332-1338.
3. Sporn M B. Nature 2011: 471: S10-S11.
4. Nolan C J, Damm P, Prentki M. Lancet 2011: 378: 169-181.
5. Emerging Risk Factors Collaboration, Seshasai S R, Kaptoge S, Thompson A et al. N Engl J Med 2011: 364: 829-841.
6. Li C, Zhao G, Okoro C A et al. Diabetes Care 2013: 36: 1569-1576.
7. Evans J M M, Donnelly L A, Emslie-Smith A M et al. BMJ 2005: 330: 1304-1305.
8. Libby G, Donnelly L A, Donnan P T et al. Diabetes Care 2009: 32: 1620-1625.
9. Duncan B B, Schmidt M I. Diabetes Care 2009: 32: 1748-1750.
10. Currie C J, Poole C D, Jenkins-Jones S et al. Diabetes Care 2012: 35: 299-304.
11. Zhang P, Li H, Tan X et al. Cancer Epidemiol 2013: 37: 207-218.
12. Badr D, Kurban M, Abbas O. J Eur Acad Dermatol Venereol 2013: 27: 1329-1335.
13. Chaudhary S C, Kurundkar D, Elmets C A et al. Photochem Photobiol 2012: 88: 1149-1156.
14. Sikka A, Kaur M, Agarwal C et al. Cell Cycle 2012: 11: 1374-1382.
15. Cerezo M, Tichet M, Abbe P et al. Mol Cancer Ther 2013: 12: 1605-1615.
16. Vitale-Cross L, Molinolo A A, Martin D et al. Cancer Prev Res 2012: 5: 562-573.
17. Byekova Y A, Herrmann J L, Xu J et al. Arch Biochem Biophys 2011: 508: 204-211.
18. Wu C L, Qiang L, Han W et al. Oncogenes 2012: 32: 2682-2689.
19. Tomic T, Botton T, Cerezo M et al. Cell Death Dis 2011: 2: e199-10.
20. Martin M J, Hayward R, Viros A et al. Cancer Discov 2012: 2: 344-355.
21. Wouters J, Stas M, Gremeaux L et al. PLoS ONE 2013: 8: e76550.
22. Schatton T, Frank M H. Pigment Cell Melanoma Res 2007: 21: 39-55.
23. Song J, Chang I, Chen Z et al. Huang S, editor. PLoS ONE 2010;5:e11456.
24. White R A, Neiman J M, Reddi A et al. J Clin Invest 2013: 123: 4390-4404.
25. Arwert E N, Hoste E, Watt F M. Nat Rev Cancer 2012: 12: 170-180.
26. Colmont C S, Harding K G, Piguet V et al. Exp Dermatol 2012: 21: 576-580.
27. Kamstrup M R, Gniadecki R, Skovgaard G L. Exp Dermatol 2007: 16: 297-301.
28. Comen E, Norton L, Massagué J. Nat Rev Clin Oncol 2011: 8: 369-377.
29. Kim M-Y, Oskarsson T, Acharyya S et al. Cell 2009: 139: 1315-1326.
30. Pienta K J, Robertson B A, Coffey D S et al. Clin Cancer Res 2013: 19: 5849-5855.
31. Hirsch H A, Iliopoulos D, Tsichlis P N et al. Cancer Res 2009: 69: 7507-7511.
32. Iliopoulos D, Hirsch H A, Wang G et al. Proc Natl Acad Sci USA 2011: 108: 1397-1402.
33. Iliopoulos D, Hirsch H A, Struhl K. Cancer Res 2011: 71: 3196-3201.
34. Hirsch H A, Iliopoulos D, Struhl K. Proc Natl Acad Sci USA 2013: 110: 972-977.